# Diagnostic and Surgical Challenges in Lacrimal Gland Pleomorphic Adenoma: A Case With Prolonged Ptosis and Acute Orbital Changes

**Authors:** Khayry Al-Shami, Falah Qudah, Karim Zinhom, Abed Elhakam El-Lababneh, Ziad Haddad, Sondos Qawasmeh, Yahia Ranjous

PMC · DOI: 10.1155/carm/4651378 · Case Reports in Medicine · 2026-03-06

## TL;DR

A rare case of a lacrimal gland tumor in a woman showed successful treatment through complete surgical removal, preventing recurrence.

## Contribution

Highlights the importance of recognizing unusual symptoms and complete tumor resection to prevent recurrence in lacrimal gland pleomorphic adenoma.

## Key findings

- Complete surgical removal of the tumor led to full recovery of ocular motility and visual function.
- Seven-month follow-up showed no signs of recurrence.
- Emphasizes the need for long-term surveillance to monitor for potential recurrence.

## Abstract

Pleomorphic adenoma of the lacrimal gland is a rare benign tumor affecting the orbital area that is usually noninfectious and gradually progressive in nature with painless proptosis.

We describe a case of a 37‐year‐old woman who presented with an unusual clinical course of ptotic history over five years with proptosis and superolateral orbital fullness emergent in the recent past. MRI showed that the mass originated in the lacrimal gland as a well‐circumscribed and heterogeneous mass without bone erosion or intracranial expansion. Laboratory investigations were normal. A bone window lateral orbitotomy was performed on the patient, where the pseudocapsule was not breached, allowing the excision of the encapsulated tumor in its entirety. Pleomorphic adenoma was diagnosed by histopathological examination. Following surgery, the patient completely recovered with regard to ocular motility, proptosis resolution, and visual function. A seven‐month follow‐up showed the lesion fully resolved, and there was no sign of relapse.

This case demonstrates the significance of the ability to identify abnormal manifestations of lacrimal gland pleomorphic adenoma and underlines its total resection as a method to avoid recurrence and malignant conversion. Surveillance over a long period is essential because it is possible that, after treatment several years ago, recurrence can take place.

## Linked entities

- **Diseases:** pleomorphic adenoma (MONDO:0008401), ptosis (MONDO:0000728)

## Full-text entities

- **Diseases:** Malignant transformation (MESH:D009369), upper eyelid ptosis (MESH:D001763), swelling (MESH:D004487), ecchymosis (MESH:D004438), epithelial tumor of (MESH:D002277), ocular pain (MESH:D058447), adenoid cystic carcinoma (MESH:D003528), afferent pupillary defect (MESH:D011681), dystopia (MESH:D014849), optic nerve compression (MESH:D009408), pain (MESH:D010146), visual loss (MESH:D014786), Lacrimal gland tumors (MESH:C562407), mucoepidermoid carcinoma (MESH:D018277), gland (MESH:D000307), proptosis (MESH:D005094), mass (MESH:C536030), hemorrhage (MESH:D006470), motility disturbance (MESH:D015154), basal cell adenoma (MESH:D000236), Ptosis (MESH:C564553), bone destruction (MESH:D001847), bone erosion (MESH:D014077), epithelial neoplasms (MESH:D009375), liver metastasis (MESH:D009362), benign orbital tumors (MESH:D009918), blood (MESH:D006402), diplopia (MESH:D004172), Gland Pleomorphic Adenoma (MESH:C563250), myoepithelioma (MESH:D009208), dacryoadenitis (MESH:D003607), lymphoma (MESH:D008223), drug allergies (MESH:D004342), PA (MESH:D008949), orbital mass (MESH:D009916), PAs (MESH:C535377)
- **Chemicals:** Artelac (-), glucose (MESH:D005947), chloramphenicol (MESH:D002701)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963930/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963930/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963930/full.md

---
Source: https://tomesphere.com/paper/PMC12963930